2 No-Brainer Stocks to Buy In Pharma
For investors who want the stability and reliable growth of an established business, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) are trusty quick picks. Both are quite profitable, cash-rich, and have a history of delivering value to shareholders in the form of dividends or stock buybacks. Importantly, each has a diverse drug development pipeline that's chock-full of late-stage programs approaching completion and potential regulatory approval for sale in the next few years. That's a lot of near-term catalysts that could reward shareholders.
What's more, Amgen and Biogen will report their third-quarter earnings and updates from several key clinical trials next month, so now might be a good time to buy. For the pair, this means that year-over-year quarterly sales revenues may soon start to rise from their single-digit levels, driving growth in the process. Let's investigate why these two companies deserve a spot in your portfolio.
Image source: Getty Images.
Source Fool.com
